{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T17:35:20Z","timestamp":1778780120597,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.jhep.2013.07.029","type":"journal-article","created":{"date-parts":[[2013,8,6]],"date-time":"2013-08-06T03:34:56Z","timestamp":1375760096000},"page":"1271-1277","source":"Crossref","is-referenced-by-count":64,"title":["Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma"],"prefix":"10.1016","volume":"59","author":[{"given":"Richard S.","family":"Finn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronnie T.P.","family":"Poon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Yau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz-Josef","family":"Kl\u00fcmpen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Tzong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon-Koo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae-You","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Gomez-Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Rodriguez-Lope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany","family":"Kunz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Paquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalila","family":"Sellami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Bruix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2013.07.029_b0005","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/jnci\/djn134","article-title":"Design and endpoints of clinical trials in hepatocellular carcinoma","volume":"100","author":"Llovet","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jhep.2013.07.029_b0010","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43\u20139006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhep.2013.07.029_b0015","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2013.07.029_b0020","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2013.07.029_b0025","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"European Organisation for Research and Treatment of Cancer. EASL-EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma","volume":"56","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2013.07.029_b0030","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2013.07.029_b0035","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.drup.2007.11.003","article-title":"Targeting the PI3K\/Akt\/mTOR pathway: effective combinations and clinical considerations","volume":"11","author":"LoPiccolo","year":"2008","journal-title":"Drug Resist Update"},{"key":"10.1016\/j.jhep.2013.07.029_b0040","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc1362","article-title":"The TOR pathway: a target for cancer therapy","volume":"4","author":"Bjornsti","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jhep.2013.07.029_b0045","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1053\/j.gastro.2008.08.008","article-title":"Pivotal role of mTOR signaling in hepatocellular carcinoma","volume":"135","author":"Villanueva","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2013.07.029_b0050","doi-asserted-by":"crossref","first-page":"8421","DOI":"10.1158\/1078-0432.CCR-04-0941","article-title":"MTOR and P70 S6 kinase expression in primary liver neoplasms","volume":"10","author":"Sahin","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2013.07.029_b0055","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/01.tp.0000252780.42104.95","article-title":"Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation","volume":"83","author":"Sieghart","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2013.07.029_b0060","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/j.1582-4934.2008.00364.x","article-title":"RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma","volume":"13","author":"Huynh","year":"2009","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.jhep.2013.07.029_b0065","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1158\/1535-7163.MCT-10-0666","article-title":"Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma","volume":"10","author":"Piguet","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jhep.2013.07.029_b0070","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1002\/cncr.26165","article-title":"Phase 1\/2 study of everolimus in advanced hepatocellular carcinoma","volume":"117","author":"Zhu","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2013.07.029_b0075","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/apt.12132","article-title":"Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma","volume":"37","author":"Shiah","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2013.07.029_b0080","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jhep.2013.07.029_b0085","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1200\/JCO.2007.14.0988","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors","volume":"26","author":"O\u2019Donnell","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2013.07.029_b0090","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1200\/JCO.2007.14.1127","article-title":"Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data","volume":"26","author":"Tanaka","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2013.07.029_b0095","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1200\/JCO.2007.14.5482","article-title":"Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors","volume":"26","author":"Tabernero","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2013.07.029_b0100","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2013.07.029_b0105","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2013.07.029_b0110","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2008.19.5511","article-title":"Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial","volume":"27","author":"Escudier","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2013.07.029_b0115","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0009-9236(01)15633-X","article-title":"Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment","volume":"70","author":"Kovarik","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jhep.2013.07.029_b0120","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.clinthera.2013.02.007","article-title":"Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study","volume":"35","author":"Peveling-Oberhag","year":"2013","journal-title":"Clin Ther"},{"key":"10.1016\/j.jhep.2013.07.029_b0125","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1002\/cncr.25931","article-title":"A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma","volume":"117","author":"Harzstark","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2013.07.029_b0130","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.clgc.2011.11.002","article-title":"Phase I trial of everolimus plus sorafenib for patients with advanced renal cell cancer","volume":"10","author":"Amato","year":"2012","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.jhep.2013.07.029_b0135","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/lt.22434","article-title":"Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation","volume":"18","author":"Gomez-Martin","year":"2012","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2013.07.029_b0140","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdt109","article-title":"Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates","author":"Kelley","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2013.07.029_b0145","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jhep.2012.06.014","article-title":"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial","volume":"57","author":"Bruix","year":"2012","journal-title":"J Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827813005448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827813005448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,14]],"date-time":"2018-10-14T04:27:03Z","timestamp":1539491223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827813005448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0168827813005448"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2013.07.029","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}